Not for use on skin around the eyes.

Moderate Potency

Moderate Potency

Not for use on skin around the eyes.

Not for use on skin around the eyes.

Bath emollients for children up to one year of age as per NICE guidelines

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

Risk of venous thromboembolism (VTE) for drospirenone-containing combined oral contraceptives (COCs), is higher than for levonorgestrel and those containing desogestrel or gestodene. The risk of VTE with drospirenone containing pills remains very small and, like other oral contraceptives, is less than that associated with pregnancy.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes as per NICE TA572

May be initiated in primary care for people with type 2 diabetes and no heart failure and for the managment of CKD in line with NICE TA 942. Empagliflozin remains as specialist recommended in the treatment of chronic heart failure (with or without T2D) - in line with NICE TA773 and TA929

May be initiated in primary care for people with type 2 diabetes and no heart failure and for the managment of CKD in line with NICE TA 942. Empagliflozin remains as specialist recommended in the treatment of chronic heart failure (with or without T2D) - in line with NICE TA773 and TA929

Enstilar foam is accepted onto the formulary as another formulation of calcipotriol and betamethasone dipropionate for patients with non-scalp psoriasis. The recommended treatment period for foam (and Dovobet ointment) is 4 weeks. If it is necessary to continue or restart treatment after this period, treatment should be continued after medical review and under regular medical supervision. General measures such as the frequent use of emollients are important in the management of psoriasis. If using other topical products containing calcipotriol in addition to Enstilar, the total dose of all calcipotriol containing products should not exceed 15 g per day.

Generic rivaroxaban (once daily) and generic apixaban (twice daily) are joint best-value DOACS for patients commencing treatment for atrial fibrillation

Generic rivaroxaban (once daily) and generic apixaban (twice daily) are joint best-value DOACS for patients commencing treatment for atrial fibrillation

Not for use on skin around the eyes.

Ulipristal acetate (ellaOne) is accepted for use as emergency hormonal contraception for women presenting between 72 to 120 hours and for whom an emergency IUD is not preferred or possible. It may also be considered for use between the 0-120 hours period when sexual intercourse has occurred at mid-cycle as it may be more effective than levornorgestrel. Note that ellaOne can be used only once per cycle, should not be used if the woman is taking concomitant enzyme inducing drugs, and does not facilitate quick start oral contraception after its use as a barrier method has to be used until next menstrual period.

for restricted use in heavy menstrual bleeding only

Please see shared care guidelines for information as to when it is suitable for GP to initiate prescribing based on cardiology advice

Please see shared care guidelines for information as to when it is suitable for GP to initiate prescribing based on cardiology advice

Please see shared care guidelines for information as to when it is suitable for GP to initiate prescribing based on cardiology advice

Apply every 2-4 hours for the first 2 days, then reduce frequency to 4 times daily (maximum of 10 days treatment).

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

The CHM recommends that no patients (male or female) under the age of 55 years should be initiated on valproate unless 2 specialists independently consider and document that there is no other effective or tolerated treatment. Please see MHRA website for further information.

Antimetabolites
For actinic keratosis for areas up to 500cm2 Additional information may be found on Cornwall RMS

Buccolam is the preferred formulation in the SCG for community paediatrics. CFT LD team also use Buccolam but may also use Epistatus occasionally in selected patients. Please note the difference in concentration between brands.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

Lisdexamfetamine (Elvanse) is accepted onto the formulary as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years of age and over when treatment with previous methylphenidate treatment has failed.

For adult patients with highly refractory epilepsy who have been heavily pretreated and remain uncontrolled.